Paul Hauptman is a Cardiology physician affiliated with University of Nevada. OpenAlex indexes 141 publications with 5,983 citations (h-index 38); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3635 Vista Ave At Grand Blvd
St Louis, MO 63110
Telephone
314-577-8896Registry record last updated 9 Jan 2008.
Clinical trials
- Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
Sponsor: Celladon Corporation
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20241 payment
- LivaNova USA, Inc.Program year20237 payments
- PFIZER INC.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
93.3%Beta blocker24.5%Metoprolol Succinate53%Carvedilol30%Metoprolol Tartrate17%Part D<11 patientsStatin18.4%Atorvastatin Calcium62%Simvastatin24%Pravastatin Sodium13%Part D<11 patients+ 10 more classes in this area
Blood & clotting
3.8%Vitamin K antagonist3.8%Warfarin Sodium100%Part D<11 patientsCancer & immunology
2.9%Calcineurin inhibitor2.9%Cyclosporine Modified100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2003–2006 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Expert Consensus on the Diagnosis and Management of Digoxin Toxicity
The American Journal of Medicine
2024 - Influence of Social Determinants of Health on Heart Failure Outcomes: A Systematic Review
Journal of the American Heart Association
2023 - Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry
European Heart Journal - Cardiovascular Pharmacotherapy
2021 - Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America
Journal of Cardiac Failure
2020
Similar KOLs
Other experts from the same institution or the same specialty.
William Graettinger, MD
University of Nevada
Buddhadeb Dawn, MD
University of Nevada
Lali Sekhon, MD, PhD
University of Nevada
Abraham Rothman, MD
University of Nevada
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”